Europe Blood Screening Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Blood screening in Europe covers testing for pathogens such as HIV, hepatitis B and C, syphilis, and emerging infectious diseases, using technologies including immunoassays, nucleic acid testing, and rapid tests. The market sits within the broader European blood testing sector, which was estimated at approximately $21.6 billion in 2024-2025, making blood screening a significant but narrower specialty segment.

• •The market was valued at approximately $4.03 billion in 2025, with projections reaching roughly $8.6 billion by the early 2030s under some scenarios.
• •Market maturity varies across Europe, with Western European countries generally having higher screening adoption rates than Eastern European nations.
• •The broader in vitro diagnostics market in Europe continues to underpin demand for blood screening products across public and private healthcare settings.

EU Regulation 2024/1938 is strengthening blood safety oversight across member states, requiring compliance that drives replacement and upgrade cycles for screening equipment. Wider insurance and national reimbursement policy changes are shifting demand dynamics, making advanced screening technologies more financially accessible across European healthcare systems.

• •Tightening EU blood safety regulatory frameworks are compelling blood banks and hospitals to adopt newer, more sensitive screening technologies.
• •Expansion of healthcare infrastructure, particularly in Eastern and Central Europe, is creating new demand for blood screening installations.
• •Favorable regulatory approvals for advanced blood screening systems are accelerating technology adoption across the region.

The market is typically segmented by technology, such as immunoassays, nucleic acid testing, and rapid tests, as well as by product type, end user (blood banks, hospitals, diagnostic laboratories), and country. Western Europe, including Germany, France, the United Kingdom, and Italy, holds the largest share due to established healthcare infrastructure and stringent regulatory standards.

• •Immunoassay and nucleic acid testing technologies dominate the screening segment, with NAT adoption increasing due to higher sensitivity for pathogen detection.
• •Eastern European markets are growing faster than Western Europe as countries modernize blood safety infrastructure and align with EU standards.
• •Blood banks represent the largest end-user segment, followed by hospitals and independent diagnostic laboratories.

What are the recent trends and outlook?

The market is moving toward more sensitive nucleic acid testing and integrated laboratory automation to reduce human error and increase throughput. Emerging infectious disease threats and pandemic preparedness considerations are likely to sustain investment in blood screening capabilities through the forecast horizon.

• •Consolidation of laboratory workflows into fully automated screening platforms is a key near-term technology trend.
• •Pathogen reduction technologies and next-generation sequencing applications are emerging as complementary approaches to traditional screening methods.
• •Harmonization of blood safety standards across the European Economic Area is expected to drive cross-border market integration and equipment standardization.